ICOS Icos

ICOS Corporation (Nasdaq:ICOS) announced today the appointment of John B. Kliewer to Corporate Vice President, in addition to his responsibilities as General Counsel and Secretary. Mr. Kliewer joined ICOS in August 2002. Commenting on the promotion, Paul N. Clark, Chairman, President and Chief Executive Officer stated, "After joining ICOS three years ago, John soon became an invaluable legal resource as well as a business advisor to ICOS. This promotion is a reflection of the value he brings from a legal and business perspective." Prior to joining ICOS, Mr. Kliewer held various positions at Immunex Corporation, most recently as Associate General Counsel. Prior to joining Immunex, he was an Associate at the law firm of Cravath, Swaine & Moore. Following law school, Mr. Kliewer clerked for the Honorable Frank J. Magill of the U.S. Court of Appeals for the Eighth Circuit. He graduated summa cum laude and received his J.D. from the Georgetown University Law Center. Mr. Kliewer is a Pacific Northwest native and received his bachelor's degree from the Henry M. Jackson School of International Studies at the University of Washington. About ICOS Corporation ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients. Through Lilly ICOS LLC, ICOS is marketing its first product, Cialis(R) (tadalafil), for the treatment of erectile dysfunction. ICOS is working to develop treatments for serious unmet medical conditions such as pulmonary arterial hypertension, benign prostatic hyperplasia, cancer and inflammatory diseases. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with product commercialization, manufacturing activities, clinical development, regulatory approvals, intellectual property claims and litigation and other risks detailed in the latest Quarterly Report on Form 10-Q and its other SEC filings.